RxDoctor Payments DataLook up a doctor →

Christopher Hoimes, DO

Hematology & Oncology · Cleveland, OHNPI 1780634188

Payments from drug & device makers

$7,487,136in general payments, 2019–2025

Across 570 payments — averaging $13,135 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$5.1M
  • Seagen Inc.$1.4M
  • Alkermes, Inc.$240K
  • Pfizer$238K
  • Biontech SE$172K
  • Mirati Therapeutics, Inc.$132K
  • plus $261K from 14 others
$8,251in research payments, 2019–2025

Across 9 payments — averaging $916.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$8K
  • Astellas Pharma Global Development$171

What the payments were for

  • Consulting fees$55,97747%
  • Speaking & faculty fees$36,22530%
  • Travel & lodging$6,2095%
  • Food & beverage$2,5402%
  • Education$17,99015%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,487,136 in reported general payments places this provider in the 95th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$59,504
Medicare patients
228
Services billed
857

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LenvimaLenvatinib Mesylate18$407,075
InlytaAxitinib18$149,833
OrgovyxRelugolix34$83,961
Abiraterone Acetate40$14,449
EliquisApixaban18$10,539
Dexamethasone17$390
Prednisone100$366
Ondansetron Hcl47$284
Triamcinolone Acetonide30$241
Prochlorperazine Maleate11$109
Oxycodone Hcl14$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Lenvima$6,343$407,07518 claims
PfizerInlyta, Eliquis$237,598$160,37236 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$16$14,44940 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →